Normal weight obesity: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Anya Craven
imported>Anya Craven
Line 123: Line 123:
==References==
==References==
{{reflist | 2}}
{{reflist | 2}}
<ref>Ruderman NB, Schneider SH, Berchtold P, (1981) The "metabolically-obese," normal weight individual, The American Journal of Clinical Nutrition 34, 1617-1621</ref>

Revision as of 17:30, 14 November 2011

All unapproved Citizendium articles may contain errors of fact, bias, grammar etc. A version of an article is unapproved unless it is marked as citable with a dedicated green template at the top of the page, as in this version of the 'Biology' article. Citable articles are intended to be of reasonably high quality. The participants in the Citizendium project make no representations about the reliability of Citizendium articles or, generally, their suitability for any purpose.

Attention niels epting.png
Attention niels epting.png
This article is currently being developed as part of an Eduzendium student project in the framework of a course entitled Appetite and Obesity at Edinburgh University. The course homepage can be found at CZ:UoE Appetite and Obesity 2011.
For the course duration, the article is closed to outside editing. Of course you can always leave comments on the discussion page. The anticipated date of course completion is 01 April 2012. One month after that date at the latest, this notice shall be removed.
Besides, many other Citizendium articles welcome your collaboration!


This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Appetite.jpg

The prevalence of obesity has risen rapidly in recent years and shows no clear signs of slowing down; thus in the USA for example, the prevalence of obesity has increased from ~13% to almost 30% from the 1960s to present time.[1]

To clinically classify a person as being obese, their Body Mass Index (BMI) must be equal to or greater than 30kg/m2. However, the spectrum of obesity is quite large. Normal Weight Obesity (NWO), found in almost half of the American adult population, is when a person has a normal BMI (18.5- 24.9 kg/m2) but also has a high percentage of body fat(>23.1% for men and >33.3% for women) as well as heart and metabolic disturbances. [2]

Measuring BMI does not take into account muscle or bone mass, and as both are denser than fat, people can have an ‘obese’ BMI while they actually have a healthy percentage of body fat. Conversely, a person can have a normal BMI and be in the normal weight range but have unhealthily high adiposity levels. High percentages of body fat tissue are high risk factors for the diseases and disorders linked to obesity, including diabetes, ischemic heart disease, heart failure, hypertension and sleep apnea. [3] Catriona Thompson 19:50, 25 October 2011 (UTC)

Measuring Normal Weight Obesity

The 'gold standard' definition of obesity is considered to be an excess in Body Fat (BF), but the BMI is used by clinicians and epidemiologists as a means of defining the presence of adiposity and/or obesity. The advantages of using the BMI instead of BF values is that it is a lot simpler to use and easy to reproduce. Studies showing the association between extreme BMI values and increased mortality further support its usage. However, this test fails to differentiate between elevated BF and preserved/ increased lean mass in patients with a BMI below 30kg/m2 - i.e. those not clinically classified as obese.

The strong relationship between high adiposity and metabolic disturbances makes it vital to try find a more accurate way in which to determine adiposity other than BMI.

The definition of metabolic syndrome covers the following criteria:

1) Waist circumference (>102 cm in men and >88 cm in women)

2) HDL (<1.04mmol/L in men and <1.03mmol/L in women)

3) Triglycerides (>1.7mmol/L)

4) Blood Pressure (systolic blood pressure >130mmHg or diastolic blood pressure >85mmHg)

5) Fasting Glucose (>5.5mmol/L)

Genetic and Environmental Factors of High Adiposity

High adiposity, specifically in abdominal regions, can serve as a positive indicator of the potential risk of cardiac disease and diabetes mellitus. [4] Both of these diseases along with other conditions are of increased risk when suffering from obesity. This high abdominal adiposity can be independent of body weight, as observed in the normal weight obesity phenotype, and can be evaluated by measuring the waist circumference, or more reliably, the waist-to-hip ratio. [3] As a high percentage of body fat in abdominal regions is closely linked to the health risks of obesity, researching the genetic and environmental causes of the obesity phenotype, central obesity, seems a practical area to look for causes of normal weight obesity.

Obesity and fatness are thought to be largely inheritable features [5] . [6] This has been concluded from several family, twin and adoption studies. However, twin studies tend to indicate heritability more so than adoption or family studies. [7] [8] Studies have also recognised genetic variance among fat deposition patterns, showing that some individuals store more fat abdominally than others. Evidence for this comes from studies between monozygotic and dizygotic twins, between biological siblings and adopted siblings and between children living with their biological parents and children living with foster parents. [9] Catriona Thompson 20:15, 14 November 2011 (UTC)

The genetic heritability of central obesity is of great interest as the disease is so closely linked to high risk health issues. Genetics cannot be the sole cause of obesity and normal weight obesity, because the human genome has not changed in the recent years that we have seen the dramatic increase in prevalence of disease. However, there are genetic factors which may make some individuals more susceptible to having a higher percentage of body fat. [10] Central obesity is more prevalent in males than females and increases with age. Family resemblances have been recognised, suggesting its heritability. Rosmond’s association studies have also shown that abdominal visceral fat levels increase in males and females with age and this increase is not only seen in obese individual but in lean people of normal BMI too.

Currently it is thought that only about 7% of the obese population is affected by monogenic causes of childhood obesity. However, the mutations which cause these forms of obesity are very uncommon. [11] Several genes have been identified as ‘obesity genes’ and although each allele would cause very little variance in BMI alone, a polygenic explanation seems more likely. This means having several high risk alleles might increase the likelihood of obesity in an individual. [12] [10]

Many of the genes that have been discovered are connected to functions of the hypothalamus and so it is thought that they have a possible role in the balance of energy input and output. However, normal weight obesity is unlikely to be caused or influenced by the same genetic mutations as all other forms of obesity. For instance, the POMC KO causes severe obesity and hyperphagia due to a lack of interactions between melanocortin and the melanocortin 4 receptor. [5] Normal weight obesity phenotype shows a high percentage of body fat in normal weight individuals but no severe obesity and there is unlikely to be any hyperphagia.

Ukkola et al hypothesised that gene interactions between polymorphisms in glucocorticoid receptor, adrenergic receptor and lipoprotein lipase genes have an effect on adiposity and regional fat distribution.

Dyslipidemia [13]

Genetic mutations would not have such a role in central adiposity without the influence of our modern plentiful environment. [4] Environment has to strongly influence the central obesity phenotype as less than 50% of cases are genetically heritable. [10]

Disorders linked to NWO

There are a large number of metabolic complications that result from excess body fat, as well as a number of mechanical complications directly associated with excess body fat (table 1 and 2). Studies involving subjects with normal BMI have reported conflicting finding to the widely held belief; that maintaining a normal weight automatically protects against disorders such as increased adiposity and tendency to develop metabolic syndrome, which often causes type 2 diabetes.

Table 1. Metabolic complications of obesity[14]

Metabolic complications of obesity
Type 2 diabetes
Hypertriglyceridemia/

Low HDL cholesterol

Hypertension
Non-alcoholic fatty liver disease/

Non-alcoholic steatohepatitis

Inflammation
Hyperuricemia (excess uric acid)
Insulin resistance
Polycystic ovarian syndrome


Table 2. Mechanical complications of obesity[14]

Mechanical complications of obesity
Gastroesophageal reflux disease
Obstructive sleep apnea
Degenerative joint disease

The effect of free fatty acids (FFA) on glucose metabolism in human has been studied extensively. Studies have established that obesity and increased plasma FFA concentrations are risk factors for the development of type 2 diabetes. Elevated plasma FFA concentrations upregulate glucose production and impair muscle glucose uptake, oxidation and storage. Increased insulin release can also result, as well as pancreatic beta-cell dysfunction.

In addition to their effects on glucose metabolism and risk of diabetes, increased FFA concentrations have been shown to associated with ischemic heart disease. [14]

To support this increase in insulin secretion, another study showed that adult-onset NWO individuals show hyperinsulinism, and also an increase in fat cell size, compared to obese patients of similar age, height and weight. The subjects in this study also showed hypertriglyceridemia, which is associated with HDL deficiency, atherosclerosis and pancreatitis. [15]

Hypertension and cholesterol cholelithiasis are also associated with obesity, and can also result in NWO individuals. These conditions have been shown to improve with caloric restriction both in obese and NWO patients. It is still not clear how subtle increases in adiposity and/or hyperinsulinism cause pathogenesis of obesity-related metabolic complications in normal weight individuals.[15]

Early inflammation and greater proinflammatory cytokine levels in plasma is also characterized in NWO women, compared to non-obese women. White body fat, or adipose tissue, is functionally similar to dynamic endocrine organ; it secretes various adipokines including proinflammatory factor, such as TNF-alpha, IL-6 and IL-1. Since they play an essential role in the onset of cardiovascular disease, atherosclerotic processes and insulin resistance, this supports the concept that NWO patients may be predisposed to develop metabolic syndrome and CV disease.[16]

Romero-Corral et al. reported that NWO is strongly associated with cardiometabolic dysregulation and a high prevalence of metabolic syndrome in these individuals is similar to that in overweight subjects. The study shows that in women, NWO is independently associated with an increased risk for CV mortality. They also found a correlation between increased waist circumference (>87cm in men and >82cm in women) and CV risk, which is a similar correlation observed with BF%. Since devices for measuring BF are not widely available in clinical practice, this study reinforces the reliability of waist circumference measurement as an alternative method of prognosis, which is easier and inexpensive.[16]

These studies show that a focus on maintaining "a healthy weight" may need to be shifted to maintaining "a healthy body fat percentage". It is important to be aware that even people with normal weight may have excessive body fat, and that they may be at risk of developing diabetes and heart disease.

Treatments and Prevention

As mentioned previously NWO is classified as having a healthy BMI, but a high percentage of fat. Therefore to effectively manage NWO, the main aim is to prevent the problems associated with NWO, such as type 2 diabetes, hypertension, hypertriglyceridemia and cardiovascular diseases. However if these associated symptoms of NWO are existing, then the aim is to control and prevent any further progression of these conditions. As well as pharmalogically treating the specific conditions, for example by taking antihypertensive drugs, diet and exercise are also very effective at controlling and treating NWO.

For individuals who are overweight and obese, the best treatment is to lose weight through a very low calorie diet. Whereas NWO individuals should be placed on a calorie controlled diet, but not as calorie restrictive as overweight/obese individuals, this will lead to a reduction in adipose tissue mass and prevent a further increase in adiposity. Calorific restriction also alleviates the associated insulin resistance. 1 Ruderman et al(2011) found a 4-12 week calorie restricted diet to be successful in treating NWO, and is some cases was the only therapy needed to treat NWO 2. A well balanced diet is also needed, for example high carbohydrate diet increases the risk of hyperinsulinism in NWO, therefore eating a low carbohydrate is beneficial.1 A Diet high in folic acid, B12, and antioxidants will protect against the development of cardiovascular diseases. 2

Through regular exercise muscle mass will increase, and lead to a reduction in fat stores, leading to a healthier BMI, with healthier adiposity levels. Exercise is of great benefit for NWO individuals as it improves insulin sensitivity.2 Ruderman et al(1981) state that exercise decreases triglycerides levels, thus decreasing the risk of high cholesterol associated diseases and diabetes. A further benefit of exercise is that it increases high density lipoproteins1. Hypertension associated with NWO can be treated with exercise which lowers blood pressure.1

The best treatment for NWO is through combining a low calorie diet with regular exercise. NWO Individuals with abnormal glucose tolerance showed a 30-50% reduction in developing type 2 diabetes, and glucose tolerance returned to normal through combinational therapy, compared to diet alone with no exercise. Thus demonstrating the importance of regular exercise on treating NWO. 2

If exercise and diet do not work, then pharmacological approaches should be used. For example thiazolidinediones are successful in treating abnormal insulin sensitivity. 2 in addititon anorexigenic drugs can treat NWO, as they cause significant weight loss and prevent type 2 diabetes. 1 Statins can be used to lower cholesterol levels, thus reducing the risk of cardiovascular diseases, whilst to lower blood pressure antihypentensives can be used.

The conditions associated with NWO such as hypertension can have dangerous consequences, therefore it would be ideal to identify people at risk of NWO earlier, so diet and exercise regims could be advised in order to prevent any further progression, in which genetic markers would be effective to establish individuals at risk.2

Conclusion

References

  1. Romero-Corral A et al. (2010) Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality Eur Heart J 31:737-46 PMID 19933515
  2. Romero-Corral A et al. (2010) Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality Eur Heart J 31:737-46 PMID 19933515
  3. 3.0 3.1 Burkhauser R V, Cawley J (2008) Beyond BMI: The value of more accurate measures of fatness and obesity in social science research J Health Economics 27: 519–29
  4. 4.0 4.1 Despre´s JP (2006) Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic riskEuropean Heart Journal Supplements 8: B4–B12
  5. 5.0 5.1 Farooqi, S. and O’Rahilly, S (2005) MONOGENIC OBESITY IN HUMANS Annu. Rev. Med. 2005. 56:443–58
  6. Despre´s JP (2006) Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic riskEuropean Heart Journal Supplements 8: B4–B12
  7. Maes, H. H. M., Neale, M. C. and Eaves, L. J. (1997) Genetic and Environmental Factors in Relative Body Weight and Human Adiposity. Behavior Genetics, 27: 4
  8. Farooqi, S. and O’Rahilly, S (2005) MONOGENIC OBESITY IN HUMANS Annu. Rev. Med. 2005. 56:443–58
  9. Hasstedt, S. J., Ramirez, M.E., Kuida,H. and Williams, R. R. (1989) Recessive Inheritance of a Relative Fat Pattern. Am. J. Hum. Genet. 45:917-925
  10. 10.0 10.1 10.2 Rosmond R (2003) Association studies of genetic polymorphisms in central obesity: a critical review. International Journal of Obesity 27: 1141–1151
  11. Frayling, T. M. et al (2007)A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity Science. 316(5826): 889–894
  12. Hofker M & Wijmenga C (2009) A supersized list of obesity genes nature genetics 41: 2
  13. Daniels S. R, (2011) Lipid concentrations in children and adolescents: it is not all about obesity. The American Journal of Clinical Nutrition. 94:699–700
  14. 14.0 14.1 14.2 Jensen M.(2009) Normal weight obesity. International Chair on Cardiometabolic Risk 2(1), 23-30
  15. 15.0 15.1 Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S (1998) The metabolically obese, normal-weight individual revisited Diabetes 47:699–713
  16. 16.0 16.1 A Romero-Corral, VK Somers, J Sierra-Johnson, Y Korenfeld, S Boarin, J Korinek, MD Jensen, G Parati and F Lopez-Jimenez,(2010) Normal weight obesity: the risk factor for cardiometabolic dysregulation and cardiovascular mortality, European Heart Journal, Vol. 31; 737-746

[1]

  1. Ruderman NB, Schneider SH, Berchtold P, (1981) The "metabolically-obese," normal weight individual, The American Journal of Clinical Nutrition 34, 1617-1621